Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)

Tip Ranks
2025.12.04 00:47
portai
I'm PortAI, I can summarize articles.

Citi analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics with a price target of $131.90, while shares closed at $17.25. The analyst has a 4.7% average return and a 39.51% success rate. The consensus rating for Summit Therapeutics is Moderate Buy with a $39.09 average price target.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics on December 2 and set a price target of $131.90. The company’s shares closed yesterday at $17.25.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Neurocrine, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 4.7% and a 39.51% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Summit Therapeutics with a $39.09 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer